Fundamental Research and Analysis of India Pharmaceutical Sector

OPEN ACCESS

Volume: 12

Special Issue: 1

Month: June

Year: 2025

P-ISSN: 2321-788X

E-ISSN: 2582-0397

Citation:
Varghese, Ancy, et al. "Fundamental Research and Analysis of India Pharmaceutical Sector." *Shanlax International Journal of Arts, Science and Humanities*, vol. 12, no. S1, 2025, pp. 124–30.

DOI:
https://doi.org/10.34293/sijash.v12iS1-June.9127

Ancy Varghese, Aneena K Santhosh & Anjana K.M
B.Com. Final Year Students
Bharata Mata College (Autonomous), Thrikkakara, Edappally, Kochi, Kerala

Ms. Reena Francis
Assistant Professor, Department of Commerce (Computer Applications)
Bharata Mata College (Autonomous), Thrikkakara, Edappally, Kochi, Kerala

Abstract
A brief analysis of the Indian pharmaceutical industry's financial health using the Altman Z- Score model. This study's objective is to evaluate the financial stability, growth potential, and investment potential of three significant companies: Cipla, Sun Pharma, and Dr. Reddy's Laboratories. Studies that concentrate on elements like R&D,operational efficiency and profitability demonstrate strength of Indian pharmaceutical business. Important conclusions from a number of studies show the industry's adaptability and growth potential, which are fuelled by innovation and market expansion.
Keywords: Pharmaceutical Sector, Stakeholders, Altman z Score, Fundamental Analysis, Research and Development

Introduction

The Indian pharmaceutical industry, which is well-known for its inventiveness and reasonably priced generic medications, is vital to the world. The purpose of this study is to analyse the sector's financial standing and prospects for expansion while offering investors and stakeholders useful information. The pharmaceutical sector in India is a significant player in the global market and is highly popular for its wide range of products, strong skill set, and significant contributions to healthcare. India has an impact on healthcare outcomes worldwide being one of the largest producers of generic drugs. Through an analysis of the sector's foundations, market dynamics, and the financial health of three major companies, this study offers a comprehensive grasp of the sector's complexity. By manufacturing generic drugs and putting cutting-edge R&D programs into place, the sector is a brilliant example of flexibility and resiliency, conquering challenges and seizing opportunities for growth and innovation.

Literature Review

Reshmi Mannaa from IBS-Gurgaon and Saurav Pathak from Transparent Value Pvt. Ltd. (2017), has out a study to look at the pharmaceutical industry's prospects for future growth. India Ratings has predicted a robust compound annual growth rate (CAGR) of 20% over the next five years. Their study looks at popular NSE-listed companies like Cipla, Sun Pharma, Ranbaxy, Aurobindo Pharma, and Lupin, assessing both their short-term trading opportunities and long-term investment possibilities. They are able to recognize Lupin, Sun Pharma, and Cipla as businesses with strong fundamentals and promising long-term prospects by fusing technical analysis using candlestick patterns and indicators like RSI and MACD with fundamental analysis based on financial ratios and operational efficiency metrics. Based on financial statements and investor sentiment analysis, the study identifies Sun Pharma and Cipla as offering strong buying signals. It also recommends short-term investments in Sun Pharma and Lupin using profit-taking strategies in accordance with resistance levels.

V. S. Prasad Kandi, P. V. Rishil Kamal and B. N. L. Pavan (2023) carried out a study highlighting the value of Economic, Industry, and Company (EIC) analysis in the context of fundamental research. The top ten pharmaceutical companies chosen based on market capitalization are the subject of their study. A key factor in their selection process is market capitalization, which is calculated by multiplying the stock price of a company by the total number of outstanding shares.

In an attempt to provide investors with information on how to make informed decisions, the study employs fundamental analysis to ascertain each company's inherent value. The investment potential of these pharmaceutical companies is determined in part by financial metrics such as liquidity, profitability, solvency, inventory turnover, earnings per share, and gross profit.

M Kaur (2018) carried out a study whose main objective was to analyze the financial statements of five pharmaceutical companies that were listed on the National Stock Exchange (NSE) between 2015–16 and 2019–2020. The objective is to assist investors in making decisions by identifying the finest stocks to purchase. Data from selected firms' financial statements, which were sourced from corporate websites, CMIE Prowess, and Money Control, were evaluated using a number of financial metrics. Among them were the following: price-to-market value ratios, the following ratios: profitability (profit margin, net profit margin, return on assets, return on equity, and earnings per share); liquidity (current ratio, quick ratio); activity (inventory turnover, debtor turnover, working capital turnover); leverage (debt ratio, equity ratio, interest coverage ratio); and earnings ratio, earnings per share. The study aims to provide light on the financial performance of pharmaceutical businesses so that investors may make wise investment decisions.

Statement of the Problem

The Indian pharmaceutical sector is a major contributor to the global healthcare landscape, with a strong reputation for producing affordable and high-quality generic medicines. Investors in mutual funds have become more interested in this industry and frequently choose it above others when making investment choices. The reasons for this choice are yet unknown, though, particularly in light of the stability and health of the industry's finances. By utilizing the Altman Z Score to analyse a company's financial health, we are attempting to determine why mutual fund investors Favor the pharmaceutical industry over other sectors when making investment decisions

Objectives

- Assess the growth potential of the Indian pharmaceutical sector.
- Identify investment opportunities in leading pharmaceutical companies.
- Analyse the financial stability of Cipla, Sun Pharma, and DR. Reddy's Laboratories.

Methodology

The study uses secondary data, including financial statements, industry reports, and Altman Z-Score analysis. Tools like PESTER and Porter's Five Forces frameworks support the evaluation.

Results and Discussion

Pestel Analysis

A PESTEL analysis of the pharmaceutical sector highlights key external factors that shape the industry:

1. Political: Drug approval procedures, costs, and research financing are influenced by government rules, healthcare laws, trade policies, and subsidies.
2. Economic: Demand, sales, and profitability are impacted by global economic circumstances, exchange rates, consumer spending power, and price sensitivity.
3. Social: An aging population, changing lifestyles, more health consciousness, and cultural differences all affect the need for drugs and treatments.
4. Technological: Advances in R&D, automation, digital health, and artificial intelligence are what propel drug discovery, production efficiency, and customized therapy.
5. Environmental: Climate change, sustainability practices, and resource availability affect production methods, costs, and the need for specific drugs.
6. Legal: The speed and expense of bringing pharmaceuticals to market are influenced by international regulations, compliance requirements, patent laws, and complex drug approval processes.

In conclusion, a complex interplay of political, economic, social, technological, environmental, and regulatory issues affects the pharmaceutical sector. To be competitive and successfully handle opportunities and difficulties, businesses need to manage these factors.

Porter's Five Forces Analysis

Pharmaceutical sector is characterized by intense competitive dynamics, as analysed through the following Porter's Five Forces:

1. Risk of Emerging Rivals: Due to high capital needs, regulatory limits, intellectual property limitations, and strong brand loyalty, it is difficult for new companies to enter the market.
2. Bargaining Power of Suppliers: Because there are few suppliers for specialized raw materials and equipment, suppliers have significant power over pharmaceutical companies when partnerships concentrate supplier control.
3. Buyers' Bargaining Power: In markets where prices are sensitive to generics and alternatives, large buyers, such governments and healthcare institutions, have considerable bargaining power. Customers' influence grows as a result.
4. Risk of Alternative Goods or Services: Biosimilars, alternative therapies, and generic medications pose significant hazards since they offer less costly alternatives to name-brand treatments.
5. Industry Rivalry: High R&D and innovation expenses, patent expirations, and mergers and acquisitions fuel intense competition among established firms, which in turn fuels market rivalry.

In conclusion, generics, supplier and buyer power, and continuous innovation all pose serious threats to the fiercely competitive pharmaceutical sector. To keep a competitive edge, businesses must manage pricing pressures and regulatory obstacles.

Table 1 Score Card Representing Financial Factors Affecting the Company’s Financial Health

Sl. No.		Cipla	Sun Pharma	Dr. Reddy
1	Sales Growth - (SCREENER: Quarterly P & L - +ve or increase in % of Sales Growth)	🟢	🟢	
2	Operating Profit Margin Growth - (SCREENER: Quarterly P & L - +ve or increase in % Operating Profit Margin)	🟢	🟢	🟢
3	Net Profit Margin - (SCREENER: Quarterly P & L - +ve or Increase in Operating Profit Margin)	🟢	🟢	🟢
4	Borrowing - (SCREENER: Balance Sheet - Decrease or Stable Borrowing)	🔴	🟢	🟢
5	Operating Activity - (SCREENER: Cash Flow - +ve or Increase in Operating Activity)	🔴	🔴	🟢
6	Net Cash Flow - (SCREENER: Cash Flow - +ve or Increase in Net Cash Flow)	🟢	🟢	🔴
7	FII Holding - (SCREENER: Share Holding Pattern - Stable or Increase in FII Investments)	🟢	🟢	🟢
8	DII Holding-(SCREENER: Share Holding Pattern - Stable or Increase in DII Investments)	🟢	🔴	🟢
9	Promoter Holding - (SCREENER: Share Holding Pattern - Stable or No decrease Promoter Holding)	🟢	🟢	🟢
10	ROE Ratio - (Money Control: Financial Statements, Ratios - +ve or increasing)	🟢	🔴	🟢
11	ROCE Ratio - (Money Control: Financial Statements, Ratios - +ve or increasing)	🔴	🟢	🟢
12	Debt to Equity Ratio - (Money Control: Financial Statements, Ratios - <1.5 or decreasing)	🟢	🟢	🟢
13	Interest Coverage Ratio - (Money Control: Financial Statements, Ratios - Positive)	🟢	🔴	🟢
14	Strength	10/13	9/13	12/13
		76.92%	69.23%	92.31%

🟢 Accepted
🔴 Not accepted

Interpretation

Provide insight to the financial strength of the company

The companies’ scores show their creditworthiness and financial capability: Dr Reddy’s scored 92.31%, indicating a high financial standing. Whereas Cipla scored 76.92%, indicating a solid financial position, In comparison to the other two corporations, Sun Pharma’s score of 69.23% indicates a much poorer financial position.

Altman z score

Cipla

Table 2

1	2	3	4 (2/3)
X1	Working Capital	Total Asset	
	11771.79	29463.28	0.400
X2	Retained Earnings	Total Asset	
	18057.03	29463.28	0.613
X3	Ebit	Total Asset	
	4,220.77	29463.28	0.143
X4	Market Capital	Total Liabilities	
	11337.8	5749.74	1.972
X5	Sales	Total Asset	
	22753.12	29463.28	0.772

$$\zeta = (0.717*X1) + (0.847*X2) + (3.017*X3) + (0.42*X4) + (0.998*X5) = 2.837$$

Interpretation

Cipla Ltd.: Z-Score: 2.837 (Grey Zone). Strong operational efficiency but needs to improve cash flow.

Sun Pharma

Table 3

1	2	3	4 (2/3)
x1	Working Capital	Total Asset	
	199555.6	807435.9	0.247
x2	Retained Earnings	Total Asset	
	436102.5	807435.9	0.540
x3	Ebit	Total Asset	
	94084.3	807435.9	0.117
x4	Market Capital	Total Liabilities	
	363452	214281.2	1.696
x5	Sales	Total Asset	
	438856.8	807435.9	0.544

$$\zeta = (0.717*X1) + (0.847*X2) + (3.017*X3) + (0.42*X4) + (0.998*X5) = 2.241$$

Interpretation

Sun Pharma: Z-Score: 2.241 (Grey Zone). Exceptional profitability but declining operational cash flow.

Dr Reddy

Table 4

1	2	3	4 (2/3)
x1	Working Capital	Total Asset	
	118534	322851	0.367
x2	Retained Earnings	Total Asset	
	200228	322851	0.620
x3	Ebit	Total Asset	
	60115	322851	0.186
x4	Market Capital	Total Liabilities	
	9977.4	89990	0.111
x5	Sales	Total Asset	
	246697	322851	0.764

$$\zeta = (0.717*X1) + (0.847*X2) + (3.017*X3) + (0.42*X4) + (0.998*X5) = 2.176$$

Interpretation

DR. Reddy's: Z-Score: 2.176 (Grey Zone). Stable growth with strong interest coverage but negative net cash flow.

Suggestions

Monitor the Altman Z-Score and other financial health indicators regularly. Conduct periodic reviews to allow for the early detection of instances of financial distress so that remedial measures can be taken early.

Improve Operational Efficiency

Improve operational efficiency by optimizing processes, reducing costs, and enhancing productivity. There can be an investment in advanced technologies and in the betterment of processes if continuous improvement initiatives are put in place.

Diversify Revenue Streams

Exploration of new markets and product diversification will make sure that companies are not overdependent on a limited range of products or geographical areas. Lesser dependence will Favor risk control from market volatility and regulatory changes.

Increase in R&D Expenditure

Investing more in the R&D endeavour will drive innovation and then create more drugs for the company. This will definitely create an edge for the company in competition, thus greatly assisting the long-term growth and profit potential of the company.

Strengthening Compliance and Quality Assurance

Keep up the stringency of regulatory compliance and quality assurance in order to ensure products are safe and efficacious. This will enhance the corporate reputation and brand value among stakeholders.

Strategic Partnerships and Collaborations

To enter into strategic partnerships and collaborations with other pharmaceutical companies, research institutions, and healthcare organizations. This might add value through shared competencies, extended reach in the market, and innovation initiatives

Focus on Sustainability and Social Responsibility

Integrate sustainability and social responsibility into business practices. Focus on environmental stewardship, community engagement, and ethical business conduct to build a positive corporate image and ensure long-term success.

Conclusion

Altman Z-score analysis shows all three companies are financially stable, and bankruptcy is not an immediate concern. Continuous monitoring, operational efficiencies, and innovation are essential for long-term growth. The financial performance of Cipla, Sun Pharma, and Dr. Reddy's Laboratories are showing that the Indian pharmaceutical sector is resilient and has immense growth potential. There is strong profitability, operational performance, and effective debt service, but constant innovation and market adaptation should take precedence since the environment is evolving. Strategic initiatives and sound financial management can ground the companies for sustainable growth and a firm position in the market as contributors to the global healthcare ecosystem.

Reference

1. CMA Panigrahi, Raksha Sharma, and Himani Dhande, published in Global Management Horizon 7, (2018) "Fundamental Analysis of Indian Pharmaceutical Companies"
2. Tamal Datta Chaudhuri from Calcutta Business School and Paritosh Kumar from ICFAI Business School, (2009) a study on "Market Perception Shift: Indian Pharmaceutical Businesses Post-2005 Patent Regime Change"
3. DR. Manjula Shastri, Assistant Professor at Amity Business School (2022), A study on "Structure and Investment Potential of the Indian Pharmaceutical Industry"
4. Reshmi Mannaa from IBS-Gurgaon and Saurav Pathak from Transparent Value Pvt. Ltd. (2017), a study on "Strategic Analysis and Investment Recommendations in the Indian Pharmaceutical Sector"
5. V. S. Prasad Kandi, P. V. Rishil Kamal and B. N. L. Pavan (2023) "Fundamental analysis of selected companies in the pharma sector in India"
6. Suzana Baresa, Sinisa Bogdan, and Zoran Ivanovic (2013) A study on "Fundamental Analysis in Stock Valuation: A Comprehensive Review"
7. Navdeep Aggarwal and Mohit Gupta (2009) "Do High Book-to-Market Stocks Offer Returns to Fundamental Analysis in India?"
8. Snehal Shah and Ayush Ajmera from Gujarat University (2022) A study on "Investment Behavior Shifts in India: A Study of Fundamental and Technical Analysis in Equity Investment"
9. Meiliani Luckieta and Ali Amran (2021) "Impact of Financial Ratios on Stock Prices: Evidence from Manufacturing Companies on the Indonesia Stock Exchange"
10. Sten A. Thoe and Joaquina Laffarga (2004). A study on "Two-Stage Multi-Criteria Procedure for Fundamental Analysis in Equities: Evidence from the Spanish Manufacturing Industry"
11. Kirtee Khubchandani and Riddhi Sanghvi (2018) "Fundamental Analysis of Stocks Listed In BSE With Reference to Pharmaceutical Industry"
12. M Kaur (2018) "a study on "Financial Performance Analysis of Pharmaceutical Companies Listed on the NSE: 2015–16 to 2019–20"